Plus   Neg

Zynex: No Pain, All Gain...

zynex oct22 lt

Shares of Zynex Inc. (ZYXI) which touched an all-time intraday high of $13.10 on October 7, 2019, a gain of a whopping 345 percent year-to-date, have given back some of the gains and trade around $10.

Zynex is a medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring, and neurological diagnostics.

The Company operates under three subsidiaries - Zynex Medical, a provider of electrotherapy pain management devices "TENS"; Zynex Monitoring Solutions, which has developed a blood volume monitoring device, and is awaiting FDA approval and CE Marking in Europe; and Zynex NeuroDiagnostics, a developer of devices for EMG and EEG diagnostic purposes in the neurology clinic markets.

The Zynex Medical segment accounts for 90% of historical revenue and Zynex NeuroDiagnostics unit contributes less than 2% of the revenue.

The Company has improved its bottom line over the years while significantly growing its revenue, as can be seen from the numbers.

Profit/(Loss)$(6.2) Mln$(2.9) Mln$0.07 Mln$7.4 Mln$9.6 Mln
Revenue$11.1 Mln$11.6 Mln$13.3 Mln$23.4 Mln$31.9 Mln

In the first half of 2019, the Company reported a net income of $4.51 million on revenue of $19.49 million.

For the third quarter, the Company expects revenue to be between $10.7 and $11.2 million, which is approximately 32% to 38% above last year's third-quarter revenue of $8.1 million.

Zynex is slated to report 2019 third-quarter financial results on Tuesday, October 29, 2019.

With 12 consecutive profitable quarters and with long-term objectives like increasing its national footprint, growing recurring revenue streams and driving value through organic growth and strategic acquisitions, Zynex is a stock worth keeping an eye on.

Zynex transitioned from being a privately held company to a publicly held company in February 2004, following a reverse acquisition, and its shares were listed on the OTCQB under ticker ZYXI. The stock was uplisted to the Nasdaq Capital Market on February 12, 2019.

ZYXI has traded in a range of $2.58 to $13.10 in the last 1 year. The stock closed Monday's trading at $10.88, up 3.82%.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT